Anemia in heart failure: should we supplement iron in patients with chronic heart failure?
Anemia has been identified as an independent prognostic factor of both morbidity and mortality for patients with congestive heart failure (CHF). The association between anemia and adverse outcomes has raised the hypothesis that anemia correction might lead to an improvement in the prognosis of patients with CHF. Nevertheless, data from large randomized trials about the effect of anemia correction on patient outcome are still lacking. Numerous clinical studies, randomized and nonrandomized, have evaluated the efficacy of erythropoietin or iron supplementation for treating anemia in patients with CHF, and their effect on patient symptoms and functional status. The superiority of any of these approaches has not been established yet. This review will discuss different treatment options for anemic patients with CHF, with emphasis on the correction of iron deficiency.
Kaldara-Papatheodorou
Elisabet E
EE
3rd Cardiology Department, University of Athens, School of Medicine, Greece.
Terrovitis
John V
JV
Nanas
John N
JN
D018798:Anemia, Iron-Deficiency / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D019587:Dietary Supplements; D004921:Erythropoietin / Q000627:therapeutic use*; D006331:Heart Diseases / Q000150:complications*; D006801:Humans; D019266:Iron, Dietary / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
D019266:Iron, Dietary; D004921:Erythropoietin